[go: up one dir, main page]

WO2008035177A3 - Combinaison d'agonistes du récepteur de la mélatonine mt1 et mt2 avec un inhibiteur de la recapture de la norépinephrine/dopamine - Google Patents

Combinaison d'agonistes du récepteur de la mélatonine mt1 et mt2 avec un inhibiteur de la recapture de la norépinephrine/dopamine Download PDF

Info

Publication number
WO2008035177A3
WO2008035177A3 PCT/IB2007/002712 IB2007002712W WO2008035177A3 WO 2008035177 A3 WO2008035177 A3 WO 2008035177A3 IB 2007002712 W IB2007002712 W IB 2007002712W WO 2008035177 A3 WO2008035177 A3 WO 2008035177A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
norepinephrine
receptor agonists
reuptake inhibitor
dopamine reuptake
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/002712
Other languages
English (en)
Other versions
WO2008035177A2 (fr
Inventor
Guy Jadot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Copharm
Original Assignee
Copharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Copharm filed Critical Copharm
Publication of WO2008035177A2 publication Critical patent/WO2008035177A2/fr
Publication of WO2008035177A3 publication Critical patent/WO2008035177A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'utilisation d'une combinaison d'agonistes du récepteur de la mélatonine MT1 et MT2 avec un inhibiteur de la recapture de la norépinephrine/dopamine (NDRI) destinée au traitement de la dépression et d'autres troubles affectifs. Cette invention concerne spécifiquement l'utilisation d'une combinaison d'agomélatine et de bupropion destinée au traitement de la dépression et d'autre trouble affectifs.
PCT/IB2007/002712 2006-09-18 2007-09-13 Combinaison d'agonistes du récepteur de la mélatonine mt1 et mt2 avec un inhibiteur de la recapture de la norépinephrine/dopamine Ceased WO2008035177A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84520106P 2006-09-18 2006-09-18
US60/845,201 2006-09-18

Publications (2)

Publication Number Publication Date
WO2008035177A2 WO2008035177A2 (fr) 2008-03-27
WO2008035177A3 true WO2008035177A3 (fr) 2008-08-07

Family

ID=39200893

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/002712 Ceased WO2008035177A2 (fr) 2006-09-18 2007-09-13 Combinaison d'agonistes du récepteur de la mélatonine mt1 et mt2 avec un inhibiteur de la recapture de la norépinephrine/dopamine

Country Status (1)

Country Link
WO (1) WO2008035177A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2713598C (fr) * 2008-01-31 2016-07-05 Takeda Pharmaceutical Company Limited Agent prophylactique ou therapeutique pour le trouble du deficit de l'attention avec hyperactivite
FR2956031B1 (fr) * 2010-02-11 2012-03-02 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc)
PL2517700T3 (pl) * 2011-04-28 2013-12-31 Zentiva Ks Farmaceutyczne dopuszczalne kokryształy n-[2-(7-metoksy-1-naftylo]acetamidu i sposoby ich wytwarzania
PH12012000132A1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239162B1 (en) * 1999-05-17 2001-05-29 St. Elizabeth's Medical Center Method for treating depression
US20030176488A1 (en) * 1999-05-17 2003-09-18 Gregory Oxenkrug Method for treating depression
WO2005002562A1 (fr) * 2003-07-04 2005-01-13 H. Lundbeck A/S Combinaison d'un inhibiteur de recaptage de la serotonine et d'agomelatine
WO2005063297A2 (fr) * 2003-12-24 2005-07-14 Sepracor Inc. Polytherapie a base de melatonine destinee a ameliorer la qualite du sommeil

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239162B1 (en) * 1999-05-17 2001-05-29 St. Elizabeth's Medical Center Method for treating depression
US20030176488A1 (en) * 1999-05-17 2003-09-18 Gregory Oxenkrug Method for treating depression
WO2005002562A1 (fr) * 2003-07-04 2005-01-13 H. Lundbeck A/S Combinaison d'un inhibiteur de recaptage de la serotonine et d'agomelatine
WO2005063297A2 (fr) * 2003-12-24 2005-07-14 Sepracor Inc. Polytherapie a base de melatonine destinee a ameliorer la qualite du sommeil

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"P.2.142 Comparative antidepressant efficacy of bupropion and escitalopram", EUROPEAN NEUROPSYCHOPHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, AMSTERDAM, NL, vol. 15, 1 January 2005 (2005-01-01), pages S453, XP005556772, ISSN: 0924-977X *
DANILEVICI TE VITA ET AL: "[Present-day approach to pharmacological and clinical aspects of novel antidepressants]", MEDICINA (KAUNAS, LITHUANIA) 2002, vol. 38, no. 12, 2002, pages 1147 - 1156, XP002481915, ISSN: 1010-660X *
DUBOCOVICH M L: "DRUG EVALUATION: AGOMELATINE TARGETS A RANGE OF MAJOR DEPRESSIVE DISORDER SYMPTOMS", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, vol. 7, no. 7, 1 January 2006 (2006-01-01), pages 670 - 680, XP008078929, ISSN: 1472-4472 *
GAO K ET AL: "NEWER TREATMENT STUDIES FOR BIPOLAR DEPRESSION", BIPOLAR DISORDERS, BLACKWELL MUNKSGAARD, DK, vol. 7, no. SUPPL. 05, 1 January 2005 (2005-01-01), pages 13 - 23, XP008056141, ISSN: 1398-5647 *
KENNEDY ET AL: "Placebo-controlled trial of agomelatine in the treatment of major depressive disorder", EUROPEAN NEUROPSYCHOPHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, AMSTERDAM, NL, vol. 16, no. 2, 1 February 2006 (2006-02-01), pages 93 - 100, XP005268530, ISSN: 0924-977X *
MILLAN ET AL: "The role of monoamines in the actions of established and ''novel'' antidepressant agents: a critical review", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 500, no. 1-3, 1 October 2004 (2004-10-01), pages 371 - 384, XP005480429, ISSN: 0014-2999 *

Also Published As

Publication number Publication date
WO2008035177A2 (fr) 2008-03-27

Similar Documents

Publication Publication Date Title
IL255201B (en) Process for preparing (r2, 1r)-3-3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
WO2008151179A3 (fr) Phénéthylamines substituées
IL196627A0 (en) Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-
MX336760B (es) Formas solidas de moduladores selectivos de receptor de androgenos.
UA84697C2 (ru) Использование (1s,2r) энантиомера милнаципрана для получения лекарственного средства
IL206197A (en) Crystalline forms of the compound (r1, r2) –3– (3– dimethylamino – 1 – ethyl – 2 – methyl-profile) –phenol processes for their preparation, pharmaceutical compositions containing them, and their use in the preparation of pain treatment compositions
MXPA05013016A (es) Gaboxadol para el tratamiento de la depresion y otros trastornos afectivos.
WO2008035177A3 (fr) Combinaison d'agonistes du récepteur de la mélatonine mt1 et mt2 avec un inhibiteur de la recapture de la norépinephrine/dopamine
TW200640454A (en) Method for treating obesity
MX2009008776A (es) Agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos.
UA87515C2 (ru) Фармацевтическая композиция толтеродина с пролонгированным высвобождением
SG143203A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
IL186373A0 (en) Use of agomelatine for obtaining medicaments used for treating bipolar disorders
WO2008079728A3 (fr) Compositions contenant un agoniste du récepteur adrénergique alpha-2b et un inhibiteur du recaptage de la sérotonine-norépinéphrine, destinées à traiter la douleur chronique
JO2631B1 (en) Use agomelatine to obtain medications to treat leukoplakia around the brain ventricles
EP1260221A3 (fr) Therapie de combinaison de la depression et de l'anxieté
WO2008006819A3 (fr) Utilisation d'agonistes de ppar-alpha pour le traitement des troubles de la fonte du muscle squelettique
MEP1908A (xx) Gabaksadol za liječenje depresije i drugih afektivnih poremećaja
ME02758B (fr) Nouvelle association entre l'agomélatine et un inhibiteur de la recapture de la noradrénaline et les compositions pharmaceutiques qui la contiennent
TW200744571A (en) Combination of β3 receptor agonist and of monoamine reuptake inhibitors, pharmaceutical composition containing it and therapeutic use thereof
WO2007109141A3 (fr) Compositions pharmaceutiques comprenant un agoniste du recepteur de melatonine et procedes d'utilisation correspondant
WO2010036773A8 (fr) Dérivés déutérisés de l-aryl-2-aminométhylcyclopropane carboxamide
WO2007136743A3 (fr) Dothiépine et procédés pour traiter les troubles du sommeil l'utilisant
WO2008066845A3 (fr) Traitement du syndrome métabolique avec de la norfluoxétine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07804943

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07804943

Country of ref document: EP

Kind code of ref document: A2